The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Open accessAbstract
mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humoral responses. Moreover, mRNAs have inherent adjuvant properties due to their complex interaction with pattern recognition receptors (PRRs). This recognition can be either beneficial in activating antigen-presenting cells (APCs) or detrimental by indirectly blocking mRNA translation. To decipher this Janus effect, we describe the different innate response mechanisms triggered by mRNA molecules and how each element from the 5' cap to the poly-A tail interferes with innate/adaptive immune responses. Then, we emphasize the importance of some critical steps such as production, purification, and formulation as key events to further improve the quality of immune responses and balance innate and adaptive immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”
From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [4]
In the citing paper
“The use of CleanCap® cap analogs reduces the probability of reverse capped, uncapped, and cap0 intermediates, and the co-transcribed mRNA only possesses a cap1 structure, therefore capping rate can be 90% or higher.52,126”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“The vaccinia capping enzyme (VCE) integrates the enzymatic activity of RTPase, GTase, and G-N7 MTase, which can be capped to generate a cap0 structure, and then 2′-O-MTase can be used to generate a methylated cap1 structure, thus reaching a capping efficiency of 100%.52”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“dsRNA can activate PRR such as TLR3,52,156 whereas ssRNA activates TLR7 and TLR8 to produce IFN-I, thus inducing inflammation in the host and interrupting mRNA translation.157,158”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Currently, nucleoside-modified mRNA vaccines employ 100% chemically modified nucleosides replacing natural nucleosides, and m1ψ is often used to replace uridine during IVT to improve the safety and stability of mRNA vaccines.52,134,172”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Uridine depletion to reduce counterproductive immune reactions can be achieved by the replacement of uridine by codon optimization, but this must be balanced with regard to transfer RNA abundance.120, 121, 122”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“The optimization of mRNA constructs, including the coding sequence, can regulate immunogenicity without incorporation of modified nucleosides.”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“Further, the 5′ cap protects the mRNA sterically from degradation by exonucleases, and it works synergistically with the poly(A) tail at the 3′ end, poly(A) binding proteins and translation initiation factor proteins to circularize mRNA and recruit ribosomes for initiating translation10,11.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“A sufficiently long tail (100–150 bp) is necessary to interact with poly(A) binding proteins that form complexes necessary for initiating translation11,12 and protecting the cap from degradation by decapping enzymes13.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“These engineered UTR sequences minimize mRNA degradation by excluding miRNA-binding sites11 and AU-rich regions in the 3′ UTR19.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Kato, H., Takeuchi, O., Mikamo, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., & Akira, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080091 · Cited by 1,649
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Flagged first, then by citations
1 of the 92 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–376 of 376
mRNA-Vaccine Platform: Features of Obtaining and Delivery of mRNA
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Биоорганическая химия · doi:10.31857/s013234232302015x · Cited by 2
mRNA therapeutics in diseases: Light inspect into a new horizon
Li, Y. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/44/20240857 · Cited by 2
The Potential of mRNA Vaccines to Fight Against Viruses
Wang, X. (2024) · Viral Immunology · doi:10.1089/vim.2024.0047 · Cited by 2
Letter to the Editor: Perspectives on mRNA Vaccine Development for Cancer
Ke, Y. (2022) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0145 · Cited by 2
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2
Farzani, T. A., Espinoza, N., Manafi, M. M., Welch, S. R., Coleman-McCray, J. D., Aida-Ficken, V., Spengler, J. R., Bergeron, É., Spiropoulou, C. F., Borges, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.17.699915 · Cited by 2
Jansen, K. U. (2021) · doi:10.33442/vt202107 · Cited by 1
Cheng, H., Zhang, H., Cai, H., Liu, M., Wen, S., & Ren, J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1282112 · Cited by 1
mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons
Mishra, G., Rathee, S., Garg, M., & Patil, U. K. (2025) · Current Drug Delivery · doi:10.2174/0115672018320938241121075859 · Cited by 1
Harnessing mRNA vaccines for viral diseases: bottleneck and breakthrough
Mishra, V. K., Ranjan, A., & Mishra, Y. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003212 · Cited by 1
Marušič, T., Seravalli, T. V., Celjar, A. M., Skok, J., & Sekirnik, R. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_9 · Cited by 1
Oleaga, A., Cano‐Argüelles, A. L., Sánchez, M. G., Vizcaíno-Marín, R., & Pérez–Sánchez, R. (2025) · Pathogens · doi:10.3390/pathogens14090914 · Cited by 1
Antigen-encoding circular single-stranded DNA for cancer vaccine
Liu, R., Ye, R., Hu, G., Chen, H., Niu, M., Wang, R., Shuai, X., Ji, Q., Li, Z., Zhang, Y., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.030 · Cited by 1
Advances in functional transcriptome analysis of Mycobacterium tuberculosis: a review
Sundaram, K., & Sridhar, R. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02374-7 · Cited by 1
mRNA vaccines for viral diseases: mechanism, advances, and future perspective
Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 1
Lv, H., Liu, W., Zhang, M., Gao, X., Liu, F., & Yang, C. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115810 · Cited by 1
Efficacy and Safety of Messenger RNA Vaccines
Batisani, K., & Chisompola, D. (2026) · Health Science Reports · doi:10.1002/hsr2.72595 · Cited by 1
Neoantigen mRNA Cancer Vaccines: How Deep Learning Is Advancing Design and Breaking Barriers
Ismail, S., & Barakat, K. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011567 · Cited by 1
Şahinci, M. N., Döşkaya, M., Karakavuk, M., Kaplan, S., Mutlu, G., Perçin, T. G., Alak, S. E., Günay-Esiyok, Ö., Gül, A., Döşkaya, A. D., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149965 · Cited by 1
mRNA-based melanoma vaccines targeting gp100 and TRP2 macromolecules
Kakroudi, M. H., Rezvanimehr, A., Zolfaghari, K., Baghaei-Shiva, G., Abbasi, H., Pourashory, M., Yazdanpanah, N., Saleki, K., & Rezaei, N. (2026) · Discover Oncology · doi:10.1007/s12672-026-04811-w · Cited by 1
RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy
Deng, Y., Xiao, M., Wan, A. H., Li, J., Sun, L., Liang, H., Wang, Q., Yin, S., Bu, X., & Wan, G. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0035 · Cited by 1
Schäfer‐Korting, M. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_696 · Cited by 1
Potential use of CRISPR/Cas13 system for vaccine development against various RNA-viral infections
Mohanty, B., Mir, R. A., Priyadarshini, A., Bhat, K. A., Barati, S., Asl, E. R., Choi, J. R., & Rasmi, Y. (2024) · Future Virology · doi:10.1080/17460794.2024.2403253 · Cited by 1
Bharat, H. A. (2022) · Acta Scientific Veterinary Sciences · doi:10.31080/asvs.2022.04.0333
Constantinescu, E. M., & Constantinescu, C.-A. (2022) · Jurnal Medical Brasovean · doi:10.31926/jmb.2021.1.5
Role of Functional Food Additives in Regulating the Immune Response to COVID-19
Verma, R., & Bagel, M. P. (2022) · Current Biotechnology · doi:10.2174/2211550111666220613143422
Mauro, V. P. (2022) · Springer eBooks · doi:10.1007/978-3-031-05616-1_10
A REVIEW ON ADVANCES AND CHALLENGES IN DEVELOPMENT OF MRNA-BASED VACCINES
Akbarizadeh-Khajeh, S., Biregani, A. F., & Doosti, A. (2022) · Studies in Medical Sciences · doi:10.52547/umj.33.3.171
Chandler, M. R., Danai, L., & Afonin, K. A. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_99-1
5‐Ethynyluridine: A Bio‐orthogonal Uridine Variant for mRNA‐Based Therapies and Vaccines
Maassen, S., Coenen, B. A., Dülk, S.-L., van der Werff, M., Warner, H. M., Spada, F., Frischmuth, T., Incarnato, D., & van den Bogaart, G. (2023) · ChemBioChem · doi:10.1002/cbic.202200658
Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00014-5
mRNA Vaccine for Infectious Disease Prevention and Cancer Immunotherapy
Dong, J. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/3/20220236
Chandler, M. R., Danai, L., & Afonin, K. A. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_99
mRNA vaccine encoding neoantigen for cancer immunotherapy using mouse melanoma as a model
Sittplangkoon, C., & Palaga, T. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.23
Nanoscale Vaccines for the Prevention of COVID-19
Iqbal, M. J., Hamdani, T., Attarwala, H. Z., & Amiji, M. M. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_13
[Research Progress of Lung Cancer Vaccines].
Fan, H., Ge, X., Zhou, X., Li, Y., Wang, A., & Hu, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.19
mRNA vaccines: a promising solution for incurable diseases
Ge, H., Hei, Y., & Wu, J. (2024) · International Conference on Biological Engineering and Medical Science (ICBioMed) · doi:10.1117/12.3021657
Mucosal mRNA Vaccines. Merits and PerspectivesPreprint
Toniolo, A., Maccari, G., & Camussi, G. (2024) · Preprints.org · doi:10.20944/preprints202402.0614.v1
IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy
Jolly, K. J., & Zhang, F. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.04.004
Dixit, N. K., & Kumar, A. (2024) · Journal of Proteins and Proteomics · doi:10.1007/s42485-024-00165-5
mRNA vaccines: the next frontier in disease prevention
Babar, Q. A., Maryam, M., MUHAMMAD, A. M., Tahir, M. F., & Ali, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00016-9
Engineered Nanomaterials Chemical Characteristics for Cancer Immunotherapy
Islam, M. A., Chowdhury, M. S., Hasan, M. J., Rayhan, M. T., Islam, S., Hossain, N., & Mobarak, M. H. (2024) · Nano LIFE · doi:10.1142/s1793984424300127
Innovations in mRNA-based cancer immunotherapy: Challenges and future directions
Essuah, M., Mbamalu, B. E., Akanmu, R. A., Kaura, S., Kareem, B. T., Ibikunle, D. E., & Hashim, H. (2024) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2024.20.2.0911
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
COVID 19: Variants, Diagnosis and Vaccines- An Update
Chauhan, P., Tiwari, A., Emmanuel, O., & Babu, M. A. (2024) · Coronaviruses · doi:10.2174/0126667975278624241224101531
Antibodies Against Melanoma Antigens – Clinical and Therapeutical Markers
Neagu, M. T., Constantin, C., Dobre, E.-G., & Zurac, S. A. (2025) · Journal of Dermatology Research · doi:10.46889/jdr.2025.6105
Mechanism of Vaccine Development
Thorat, N. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-86185-7_4
Bene, A. D., D’Aniello, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Benedetti, R., Altucci, L., Cosconati, S., Maro, S. D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00032g
Hydroxychloroquine decouples reactogenicity from efficacy in mRNA and viral-vector gene deliveryPreprint
Lainšček, D., Malenšek, Š., Golob-Urbanc, A., Orehek, S., Bohinc, J., Keber, M. M., Sotošek, T., Esih, H., Forstnerič, V., Pečan, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.10.687670
Che, S., Li, Z., Su, Z., Li, Z., Yu, A., Liu, M., & Zhang, S. (2026) · CHINESE JOURNAL OF CATALYSIS (CHINESE VERSION) · doi:10.1016/s1872-2067(25)64860-1 · Cited by 1
An overview of the mRNA applications and their therapeutic functions in clinical development
Ramakrishnaiah, T. N., Srikar, K. S., Deb, A., Ahmed, K. S., Chandraghatgi, R. R., Sarin, Y., Roopini, K., & Rajashekara, S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101413
Yilmaz-Ozturk, R., Yuka, S. A., & Çakır-Koç, R. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00759-7
Che, S., Li, Z., Su, Z., Yu, A., Liu, M., & Zhang, S. (2026) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.5c12019
Wu, J., Szakos, A., Bozóky, B., & Székely, L. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-05948-6
Duan, L. L., Zhu, H., Chen, C., & Liu, W. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00226-3
Sanjeev, A., Hannigan, C., Garrity, R., Kamalakkannan, D. S., Clendaniel, V., Mantri, M., Glass, Z., Kasiewicz, L. N., Leipheimer, J., Khan, Z., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201722
mRNA therapeutics for inflammatory bone diseases: opportunity and challenge
Huang, Y., Huang, X.-H., Mao, H., & Zhang, L. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126793
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Self-citationVectorisation d'ARN par voie orale et parentérale
Stalder, T. (2024) · theses.fr (ABES) · doi:10.70675/d509592fzbb96z4f17zb286z5040de22fd65
mRNA Vaccines: A Transformative Technology with Applications Beyond
Razi ur Rahman, M., & P, M. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00200
Krog, T. F., Haukland, I. S., & Haugland, G. T. (2026) · Vaccines · doi:10.3390/vaccines14050367
Chen, S. T., Li, R., Zhu, Y., Sun, J., & Chen, J. K. (2026) · Microorganisms · doi:10.3390/microorganisms14051000
Computational Design of mRNA-Based Cancer Immunotherapies
Kovačić, D., Huseinbegović, S. I., Muratović, A. K., & Jahibasic, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-20428-8_2
mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications
Xu, W., Wang, J., Liu, X., Lü, M., Zhang, Z. K., & Li, L. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1821852
Owen, G. R., Evans, C. A., Nair, A., Ross, S. J., Glenister, M. A., Kis, Z., & Dickman, M. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.02.735822
A Comprehensive Review of COVID-19 Vaccines: Development, Efficacy, Safety, and Immunity
Ehsan, H. (2026) · Journal of Immunology and Clinical Microbiology · doi:10.58854/jicm.1790747
Cancer vaccines as targeted therapies: translational advances and challenges
Shafaghat, Z., Sadri, M., Roozbehani, M., Kheiri, F., Dorfaki, M., & Faraji, F. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2728542
Next-generation CAR therapies enabled by mRNA engineering and delivery
Zhao, Q., Wen, Q., Pu, P., Xu, C., Hu, Q., Zhou, Z., Hua, X., & Zhang, X. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.001
Multi-attribute characterisation of mRNA via MazF endoribonuclease and LC-MS workflowsPreprint
Welbourne, E. P., Owen, G. R., Wright, L. P., Trabulo, S. M. D., Kis, Z., & Dickman, M. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.23.753728
Lainšček, D., Malenšek, Š., Forstnerič, V., Golob-Urbanc, A., Orehek, S., Bohinc, J., Keber, M. M., Sotošek, T., Esih, H., Pečan, P., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.033
Pawłuszkiewicz, K., Faltus, A. M., Zdych, M., Nowak, E., & Paluch, E. (2026) · Molecules · doi:10.3390/molecules31193427
Bioengineering strategies for improving the immunogenicity of mRNA vaccines
Wang, H., Zhuo, R., Wu, J., & Ouyang, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02991-z
Wang, Y., Ge, Y., Chen, Y., 杨永峰, & Li, J. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01857-9
Metadata
- Authors
- Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B.
- Affiliations
- Lyon 1 Université (FR)
- Corresponding author
- Verrier, Bernard
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 26
- Issue
- 3
- Pages
- 311-323
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2986812831
- Cited by
- 376
- References
- 92
- Citations by year
- 2026: 43 · 2025: 67 · 2024: 65 · 2023: 69 · 2022: 76 · 2021: 47 · 2020: 9
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Trends in Molecular Medicine (acceptedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- EuroNanoMed III
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Fondation Mérieux
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- mRNA vaccines, innate immune response, adaptive immune response, pattern recognition receptors, antigen-presenting cells, 5' cap, poly(A) tail, mRNA translation inhibition, vaccine formulation
- MeSH terms
- mRNA Vaccines, Animals, Humans, Immunity, Innate, RNA, Messenger, Vaccines, Synthetic, Receptors, Pattern Recognition, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
